ClinicalTrials.gg
CompletedNCT00867698ASTUTEUpdated Jun 18, 2014

AST-120 Used to Treat Mild Hepatic Encephalopathy

A Phase 2 interventional study of AST-120 in Mild Hepatic Encephalopathy, sponsored by Ocera Therapeutics. Completed at 38 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-06-18.

Sponsored by Ocera Therapeutics (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies in Hepatic Encephalopathy with a site in United States — 9 open to participants now, 13 under way, 1 of them phase 3. Hepatic Encephalopathy · United States.

Enrollment
10th of 58
148 · median 39
Started
2009
with 2 others
Phase 2
18 of 70
1 open now
Registered
9th of 70
by date
Lead sponsor
2 of 70
Ocera Therapeutics

Among the 70 studies in Hepatic Encephalopathy with a site in United States, this one is the 10th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2009, is one of 18 in phase 2, and was the 9th registered.

Hepatic Encephalopathy

225 studies on the registry are indexed under Hepatic Encephalopathy; 53 are open to participants now.

Browse Hepatic Encephalopathy studies →

Open to participants now

9 of the 70 studies in Hepatic Encephalopathy with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Hepatic Encephalopathy studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Hepatic Encephalopathy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether AST-120 is safe and effective in the treatment of mild hepatic encephalopathy.

03

Conditions studied

  • Mild Hepatic Encephalopathy

Keywords

  • Hepatic encephalopathy
  • Mild hepatic encephalopathy
  • HE
  • MHE
  • Cognitive impairment
  • Cognitive dysfunction
  • Liver Disease
  • Cirrhosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed cirrhosis of any cause
  2. Abnormal RBANS global summary score
  3. Grade 0 or 1 hepatic encephalopathy by West-Haven Scale
  4. MELD score \< or = 25
  5. Females must be , surgically incapable of bearing children or practicing a reliable method of

Exclusion criteria

Exclusion Criteria:

  1. Previous participation in any trial involving -120
  2. History of TIPS or surgically created portocaval shunt
  3. Treatment for overt HE within the past 3 months
  4. Use of lactulose, rifaximin, neomycin or other antibiotics in the past 7 days
  5. Active alcohol abuse
  6. Psychosis or organic brain syndromes due to alcohol or other causes
  7. Use of interferon and sedating or cognition-altering drugs
  8. Undergoing chemotherapy or radiotherapy for the treatment of cancer
  9. Active GI bleeding within the past 3 months
  10. Presence of an active infection
  11. Presence of signs and symptoms of severe dehydration
  12. Other major physical or major psychiatric illness within the past 6 months
  13. Pregnant, breast feeding, or planning to become pregnant during the study
  14. Using hormonal as the only method of birth control
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    AST-120 (6g)

    2 grams TID

    Drug: AST-120

  • Placebo comparator
    Placebo A

    2 grams TID

    Drug: AST-120

  • Experimental
    AST-120 (12g)

    4 grams TID

    Drug: AST-120

  • Placebo comparator
    Placebo B

    4 grams TID

    Drug: AST-120

Interventions

  • DrugAST-120

    Drug pages: AST 120 · Charcoal

    AST-120

    Also known as: Spherical carbon adsorbent

06

What researchers measure

Primary outcomes

  1. Neurocognitive improvement, defined as the change in the global summary score of the RBANS at Week 8 compared to Baseline.

    Time frame: 8 weeks

07

Study locations

38 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • UCSF - Fresno Community Regional Medical Center
    Fresno, California 93721, United States
  • UCSD Medical Center
    La Jolla, California 92161, United States
  • Scripps Clinic
    San Diego, California 92037, United States
  • UCSD Medical Center
    San Diego, California 92101, United States
  • California Pacific Medical Center
    San Francisco, California 94115, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32610, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • University of Miami, Division of Hepatology / Center for Liver Disease
    Miami, Florida 33136, United States
  • Northwestern University, Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • VA Medical Center / University of Iowa Hospital and Clinics
    Iowa City, Iowa 52246, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Delta Research Partners, LLC
    Monroe, Louisiana 71201, United States
  • Tulane University Health Sciences Center
    New Orleans, Louisiana 70112, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconnes Medical Center, Harvard Medical School
    Boston, Massachusetts 02215, United States
  • University of Massachusetts Memorial Medical Center
    Worcester, Massachusetts 01655, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Weill Medical College of Cornell
    New York, New York 10021, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • University of Cincinatti
    Cincinatti, Ohio 45267, United States
  • Case Western Reserve / MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Temple University Hospital
    Philadelphia, Pennsylvania 19140, United States
  • Albert Einstein Medical Center, Division of Hepatology
    Philadelphia, Pennsylvania 19141, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Medical University of Southern Carolina
    Charleston, South Carolina 29425, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390-9151, United States
  • Advanced Liver Therapies, St. Luke's Episcopal Hospital/Baylor College of Medicine
    Houston, Texas 77030, United States
  • Permian Research Foundation
    Odessa, Texas 79761, United States
  • University of Utah Health Sciences Center
    Salt Lake City, Utah 84132, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Apr 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2009
First posted
Mar 24, 2009
Start
Mar 2009
Primary completionActual
Apr 2010
CompletionActual
Jun 2010
Results delay requested
Jul 26, 2013
Last update
Jun 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00867698
Lead sponsor
Ocera Therapeutics
First posted
Mar 24, 2009
Start date
Mar 2009
Primary completion
Apr 2010
Completion
Jun 2010
Last update
Jun 18, 2014

Study contacts

Jeff Bornstein, MD
study director · Ocera Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AST 120 · Charcoal

Start the discussion